

## GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation

Braden S. Jensen,<sup>1</sup> Tobias Willer,<sup>2</sup> Dimah N. Saade,<sup>1</sup> Mary O. Cox,<sup>3</sup> Tahseen Mozaffar,<sup>4</sup> Mena Scavina,<sup>5</sup> Vikki A. Stefans,<sup>6</sup> Thomas L. Winder,<sup>7,8</sup> Kevin P. Campbell,<sup>2</sup> Steven A. Moore,<sup>3</sup> and Katherine D. Mathews<sup>1\*</sup>

<sup>1</sup>Departments of Pediatrics and Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa; <sup>2</sup>Howard Hughes Medical Institute, Departments of Molecular Physiology and Biophysics, Neurology, and Internal Medicine, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, Iowa; <sup>3</sup>Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa; <sup>4</sup>Departments of Neurology and Orthopaedic Surgery, University of California, Irvine, California; <sup>5</sup>Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware; <sup>6</sup>Departments of Pediatrics and Physical Medicine and Rehabilitation, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas; <sup>7</sup>Invitae Corp., San Francisco, California; <sup>8</sup>Prevention Genetics, Marshfield, Wisconsin

Communicated by Mireille Claustres

Received 9 June 2015; accepted revised manuscript 12 August 2015.

Published online 27 August 2015 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22898

**ABSTRACT:** Mutations in GDP-mannose pyrophosphorylase B (GMPPB), a catalyst for the formation of the sugar donor GDP-mannose, were recently identified as a cause of muscular dystrophy resulting from abnormal glycosylation of  $\alpha$ -dystroglycan. In this series, we report nine unrelated individuals with GMPPB-associated dystroglycanopathy. The most mildly affected subject has normal strength at 25 years, whereas three severely affected children presented in infancy with intellectual disability and epilepsy. Muscle biopsies of all subjects are dystrophic with abnormal immunostaining for glycosylated  $\alpha$ -dystroglycan. This cohort, together with previously published cases, allows preliminary genotype–phenotype correlations to be made for the emerging GMPPB common variants c.79G>C (p.D27H) and c.860G>A (p.R287Q). We observe that c.79G>C (p.D27H) is associated with a mild limb-girdle muscular dystrophy phenotype, whereas c.860G>A (p.R287Q) is associated with a relatively severe congenital muscular dystrophy typically involving brain development. Sixty-six percent of GMPPB families to date have one of these common variants.

Hum Mutat 00:1–5, 2015. © 2015 Wiley Periodicals, Inc.

**KEY WORDS:** GMPPB; dystroglycanopathy; limb-girdle muscular dystrophy; congenital muscular dystrophy; congenital myasthenic syndrome

Mutations in GMPPB (MIM #615320) encoding GDP-mannose pyrophosphorylase B (GMPPB) have recently been shown to cause muscular dystrophy resulting from hypoglycosylation of  $\alpha$ -dystroglycan [Carss et al., 2013]. Related disorders of  $\alpha$ -dystroglycan O-mannosylation (referred to as dystrogly-

canopathies) are known to cause a wide spectrum of clinical disorders ranging from mild limb-girdle muscular dystrophy (LGMD) to severe congenital muscular dystrophy with central nervous system and eye involvement [Godfrey et al., 2007; Bonnemann et al., 2014]. To date, there are few genetically verified individuals with GMPPB-associated dystroglycanopathy reported in literature; these individuals have a wide range of phenotypes, similar to the other dystroglycanopathies [Carss et al., 2013; Raphael et al., 2014; Belaya et al., 2015; Cabrera-Serrano et al., 2015]. Most recently, variants in GMPPB were reported to cause congenital myasthenic syndrome [Belaya et al., 2015].

Alpha-dystroglycan is a highly glycosylated protein integral to maintaining structural stability in striated muscle, supporting a variety of functions in myelinating Schwann cells, and anchoring radial glia endfeet during brain development [Michele et al., 2002; Moore et al., 2002; Saito et al., 2003]. In all these sites,  $\alpha$ -dystroglycan links the extracellular matrix to the cell surface membrane through its interactions with the transmembrane  $\beta$ -dystroglycan and a variety of extracellular matrix proteins [Barresi and Campbell, 2006]. Defects in the glycosylation of  $\alpha$ -dystroglycan reduce its binding to laminin and other extracellular ligands, compromising the function of the dystrophin–glycoprotein complex and other proteins associated with  $\alpha$ -dystroglycan [Michele et al., 2002; Barresi and Campbell, 2006]. There are currently 18 genes known to be involved in the proper glycosylation of  $\alpha$ -dystroglycan, with GMPPB being among the most recently identified [Carss et al., 2013]. GMPPB facilitates the formation of the sugar donor GDP-mannose and pyrophosphate from mannose-1-phosphate and GTP, a very early step in the glycosylation pathway. GDP-mannose is used directly for N-glycosylation or converted to dolichol-phosphate mannose (Dol-P-Man) through the Dol-P-Man synthase enzyme complex. Dol-P-Man serves as a reagent for N-glycosylation, O-mannosylation, C-mannosylation, and glycosylphosphatidylinositol anchor formation [Carss et al., 2013]. While GMPPB functions early in the glycosylation pathway, transferrin isoelectric focusing, a screening test for N-glycosylation defects seen in the congenital disorders of glycosylation, is normal in those GMPPB-associated dystroglycanopathy individuals who have been tested [Carss et al., 2013; Raphael et al., 2014].

Here, we describe the clinical, genetic, and pathological findings in nine unrelated individuals with compound heterozygous variants in GMPPB. All unreported individuals known to the authors with GMPPB variants thought to be pathogenic were included in

Additional Supporting Information may be found in the online version of this article.

\*Correspondence to: Katherine D. Mathews, Department of Pediatrics, The University of Iowa, 200 Hawkins Dr., Iowa City, IA 52242. E-mail: katherine-mathews@uiowa.edu

Contract grant sponsors: Iowa Wellstone Muscular Dystrophy Cooperative Research Center (U54-NS053672); NCATS CTSA (U54-TR001013); MDA (grant 238219).

**Table 1. Summary of *GMPPB* Case Clinical Data**

Case	P1	P2	P3	P4	P5	P6	P7	P8	P9
Gender	Male	Male	Male	Male	Female	Female	Female	Female	Male
Age at presentation	17 years	17 years	15 years	23 years	5 years	9 months	Infancy	7 months	Birth
Current age (year)	50	26	32	25	20	5	15	13	3
GMPPB mutation - allele 1	c.79G>C (p.D27H)	c.79G>C (p.D27H)	c.79G>C (p.D27H)	c.79G>C (p.D27H)	c.721C>T (p.P241S) <sup>a</sup>	c.860G>A (p.R287Q)	c.860G>A (p.R287Q)	c.860G>A (p.R287Q)	c.94C>T (p.P32S) <sup>a</sup>
GMPPB mutation - allele 2	c.1069G>A (p.V357I)	c.1069G>A (p.V357I)	c.760G>A (p.V254M) <sup>a</sup>	c.402+1G>A <sup>a</sup>	c.1034T>C (p.V345A) <sup>a</sup>	c.656T>C (p.I219T)	c.395C>G (p.S132C) <sup>a</sup>	c.859C>T (p.R287W) <sup>a</sup>	Not yet identified
Prenatal findings	None	None	None	None	None	Lost twin to hemorrhage	None	None	Decreased fetal movements; intrauterine growth restriction
Presenting signs and symptoms	Muscle weakness	Exercise induced myalgia, weakness, myoglobinuria	Muscle weakness; waddling gait	Incidental hyperCKemia with routine blood work; myoglobinuria	Muscle weakness	Developmental delay; hypotonia	Developmental delay; unusual movement patterns	Microcephaly; developmental delay; seizures; torticollis	Microcephaly; developmental delay; micrognathia; hypotonia; dysphagia; hypoxia
Maximal motor ability	Weight lifting; sports	Weight lifting; sports	Manual labor; junior high sports	Weight lifting; manual labor	Walks independently	Run; climb stairs	Walks independently; feeds orally	Able to sit; crawl	Unable to sit independently
Cognitive function	Normal intelligence	Normal intelligence	Normal intelligence	Normal intelligence	Moderate-severe intellectual disability; verbal	Moderate-severe intellectual disability; verbal	Severe intellectual disability; verbal	Severe intellectual disability; nonverbal	Severe intellectual disability; nonverbal
Epilepsy	No	No	No	No	No	No	Yes	Yes	Yes
Ophthalmologic	None	None	None	None	None	Strabismus; no saccadic movements or smooth pursuits	None	Optic atrophy; strabismus	Optic atrophy; strabismus
Cardiac	Ischemic heart disease	Normal	Normal	First-degree AV block	Normal	Normal	Normal	Normal	Bicuspid aortic valve
Respiratory function	Normal	Normal	Normal	Normal	Moderate restrictive lung disease	Normal	Normal	Normal	Nocturnal desaturation
Maximum CK (IU/l)	1,331	7,250 <sup>b</sup>	3,693	5,900	7,112	2,867	6,908	2,789	6,158
Other	None	None	None	None	Neuromuscular scoliosis; sensorineural hearing loss	None	Self-stimulatory behavior	Neuromuscular scoliosis; gastrostomy tube	Gastrostomy tube; self-stimulatory behavior
Brain MRI	ND	ND	ND	ND	Normal	Normal	Normal	Ventriculomegaly; prominent cortical sulci, cerebellar hypoplasia	Ventriculomegaly; hypomyelination; cerebellar hypoplasia
Diagnostic category	LGMD	LGMD	LGMD	LGMD	LGMD-MR	CMD-MR	CMD-MR	CMD-CRB	CMD-CRB

<sup>a</sup>novel mutation.<sup>b</sup>52,010 during an episode of rhabdomyolysis.

CMD-CRB, congenital muscular dystrophy with cerebellar involvement; CMD-MR, congenital muscular dystrophy with mental retardation; LGMD, limb-girdle muscular dystrophy; LGMD-MR, limb-girdle muscular dystrophy with mental retardation; ND, not done.

DNA mutation numbering is based on cDNA sequence. All cases were submitted to the LOVD database ([http://www.dmd.nl/nmdb/home.php?select\\_db=GMPPB](http://www.dmd.nl/nmdb/home.php?select_db=GMPPB)).

this case series. Clinical data were collected through retrospective chart review by the primary clinician. Diagnostic genetic testing was done through Prevention Genetics (RefSeq NM\_013334.2) or the University of Iowa Department of Pathology (P4, RefSeq NM\_013334.3), and deidentified reports were reviewed for all cases. Case clinical features are summarized in Table 1. Each was assigned a phenotype according to the system proposed by Godfrey et al. (2007), ranging in this series from LGMD to congenital muscular dystrophy with cerebellar involvement (CMD-CRB). All individuals had elevated maximal serum creatine kinase (CK) levels ranging from 1,331 to 7,250 (CK during episodes of rhabdomyolysis not included) and dystrophic muscle pathology. Compound heterozygous

variants or a single heterozygous variant in *GMPPB* were found in each individual.

P1, P2, and P3 each presented in their mid-to-late teens with inability to keep up with their peers and proximal weakness. P2 presented only with exercise induced myalgias, weakness, and myoglobinuria with recovery to normal strength. They are now of 50, 26, and 32 years old, respectively. All three individuals continue to walk independently and have normal cognitive and cardiopulmonary function.

P4, now 25 years old, presented at the age of 23 years after routine blood work showed elevated transaminases. Follow-up CK was greater than 5,000 U/L. He has normal strength with infrequent

episodes of exercise-induced myoglobinuria. He is cognitively normal and has a first degree AV block and low normal left ventricular systolic function (EF estimated at 50%–55%).

P5, now 20 years old, presented at 5 years old with inability to run or climb stairs. She is no longer ambulatory and developed scoliosis requiring surgery. Her pulmonary function is slowly declining with a restrictive pattern. Echocardiogram is normal but with a gradually declining ejection fraction. She has intellectual disability and requires speech therapy. She has sensorineural hearing loss.

P6, now 5 years old, presented at 9 months with hypotonia, global developmental delay, and strabismus. She is now able to walk independently and run but is ataxic. On examination, she has mild proximal weakness and full strength distally. She has intellectual disability but is able to communicate in sentences. She had obstructive sleep apnea that improved after a tonsillectomy; her cardiopulmonary function is otherwise normal.

P7 is a 15-year-old female who presented in infancy with motor and language delays and unusual movement patterns. She walked at 16 months and continues to walk independently. She has a very mild proximal weakness that has been stable over time. She developed a seizure disorder at 8 years of age and is verbal but with significant intellectual disability. Serum transferrin isoelectric focusing was normal.

P8 is a 13-year-old female who presented at 8 months of age with microcephaly, hypotonia, global developmental delay, and infantile spasms. She remained nonverbal, reportedly crawled briefly at 1.5 years but lost that skill by 2 years; she is unable to sit without support and has cortical visual impairment and strabismus. She fed orally but required a gastrostomy tube at 5 years for dietary supplementation while she continued to take food by mouth. She developed neuromuscular scoliosis requiring spinal fusion. Brain MRI at the age of 3 years showed mild cerebellar hypoplasia (Fig. 1A).

P9, now 3 years old, presented prenatally with intrauterine growth restriction and decreased fetal movements. He was hypotonic, in respiratory distress at birth, and continues to require overnight oxygen support. He never fed orally, requiring gavage or gastrostomy feeds. He developed complex partial seizures at 22 months of age controlled with levetiracetam. He is nonverbal, is unable to sit independently, and has cortical visual impairment, strabismus, and displays self-injurious and self-stimulatory behaviors. Brain MRI at the age of 19 months showed cerebellar hypoplasia (Fig. 1A). Serum transferrin isoelectric focusing was normal. An extended dystroglycanopathy genetic testing panel identified a single variant in *GMPPB* that is predicted to be pathogenic; the panel was otherwise normal. Based on phenotype, CK, muscle biopsy, and normal sequencing for other known dystroglycanopathy genes, we propose that a second variant in *GMPPB* is present, but not identifiable with commercially available testing.


Muscle biopsies of all cases were reviewed at The University of Iowa. Frozen sections from each biopsy were evaluated by hematoxylin and eosin staining and by immunofluorescence as reported previously [Moore et al., 2006]. The antibodies used for the immunostaining or western blotting reported here include I1H6 and VIA4-1 anti-glyco- $\alpha$ -dystroglycan, Shp5 anti- $\alpha$ -dystroglycan core protein, 7D11 anti- $\beta$ -dystroglycan, and ab15277 antidystrophin antibodies. Biopsies displayed dystrophic features of varying severity including myonecrosis and regeneration, increased internally placed nuclei, increased fiber size variation, and endomysial fibrosis in the more severe cases (Fig. 1C). Immunofluorescence evaluation using I1H6 and VIA4-1 antibodies against glycosylated  $\alpha$ -dystroglycan showed mosaic patterns of decreased

staining, whereas dystrophin and  $\beta$ -dystroglycan appeared normal (Fig. 1C). Wheat germ agglutinin (WGA) preparations from pooled cryosections were utilized for western blots of  $\alpha$ -dystroglycan and  $\beta$ -dystroglycan using published protocols [Michele et al., 2002]. Skeletal muscle WGA preparations from P2 showed reduced signal for glycosylated  $\alpha$ -dystroglycan and a reduction in molecular weight for core  $\alpha$ -dystroglycan compared with controls (Fig. 1B). The glycosylation status of  $\alpha$ -dystroglycan in subject fibroblast cultures was evaluated with western blots using WGA-enriched cell lysates according to published protocols [Willer et al., 2012]. Western blot analysis of WGA preparations of cultured skin fibroblasts from P2 showed no significant difference in  $\alpha$ -dystroglycan glycosylation compared with control fibroblasts (Fig. 1B). Western blot analysis of the muscle biopsy (P1) and fibroblast cultures (P3, P4, P7, P8, and P9) from other cases yielded results similar to P2 (data not shown).

In our nine cases, six *GMPPB* variants were previously reported as pathogenic, whereas five variants are novel. Based on clinical phenotypes and immunofluorescence demonstrating decreased glycosylation of  $\alpha$ -dystroglycan in muscle, we propose that these additional variants are also pathogenic. In silico analysis of the novel variants using SIFT, Mutation-Taster, and PolyPhen2 produced the following predictions: two novel variants [c.395C>G (p.S132C), and c.94C>T (p.P32S)] are predicted pathogenic by all three programs, whereas the two novel variants in P4 [c.721C>T (p.P241S), c.1034T>C (p.V345A)] were predicted pathogenic by one of the three programs (Supp. Tables S1 and S2). Sequence alignments of these novel variants are shown in Supp. Figure S1. The final novel variant in P4 (c.402+1G>A) alters a highly conserved position in the intron 4 splice donor site. Sequencing of *GMPPB* in the parents of P7 confirmed heterozygous carrier status for each parent, providing further evidence for the pathogenicity of the novel variant c.395C>G (p.S132C).

These individuals together with previously reported cases show a remarkable range in phenotypic severity, from a minimally symptomatic adult at the age of 25 years (P4) to infants with congenital muscular dystrophy including cerebellar involvement (P8, P9). They share features typical of other dystroglycanopathies including serum CK levels greater than five times normal, evidence of myonecrosis and regeneration on muscle biopsy, and abnormal  $\alpha$ -dystroglycan glycosylation by immunostaining and western blots of muscle. Electrophysiological testing for myasthenia was not completed in our cases. In contrast to skeletal muscle, the  $\alpha$ -dystroglycan glycosylation defect in cultured fibroblasts of affected individuals is absent or very mild (Fig. 1B) [Carss et al., 2013].

To date, all but six of the reported 41 individuals with *GMPPB* variants have been compound heterozygotes, making it difficult to confirm genotype–phenotype correlations. However, two variants have been seen frequently enough in *GMPPB* compound heterozygotes to provide initial insight: c.79G>C (p.D27H) and c.860G>A (p.R287Q). Sixty-eight percent of individuals (28 of 41) and 66% of the families (21 of 32) reported to date, including the present series, have one of these proposed common variants [Carss et al., 2013; Raphael et al., 2014; Belaya et al., 2015; Bharucha-Goebel et al., 2015; Cabrera-Serrano et al., 2015]. Based on data available by the NHLBI Exome Sequencing Project, the mean allelic frequency for the c.79G>C (p.D27H) and c.860G>A (p.R287Q) variants in European Americans is 0.12% and 0.02%, respectively. For comparison, the c.826C>A common pathogenic variant in *FKRP* (MIM #606596), another dystroglycanopathy-associated gene, has a mean allelic frequency of 0.07% in European Americans. The c.79G>C (p.D27H) variant has been found in 17 individuals from 12 unrelated families [Carss et al., 2013; Belaya et al., 2015; Bharucha-Goebel et al., 2015;



**Figure 1.** **A:** Sagittal T1 brain MRIs showing cerebellar hypoplasia in P8 at 3 years (A1) and P9 at 19 months (A2). **B:** Alpha- and  $\beta$ -dystroglycan were evaluated by western blot in case P2. WGA-enriched homogenates of cultured skin fibroblasts (Fib) and muscle biopsy (MB) were blotted with the core  $\alpha$ -dystroglycan antibody, Shp5 (core  $\alpha$ -DG), and the glycoepitope-dependent  $\alpha$ -dystroglycan antibody, IIH6 (glyco  $\alpha$ -DG). Subject muscle shows lower molecular weight, hypoglycosylated  $\alpha$ -DG with Shp5, and a decreased amount of functional, properly glycosylated  $\alpha$ -DG with IIH6 as compared with control. In contrast, subject fibroblasts appear similar to control. An antibody against core  $\beta$ -dystroglycan, core  $\beta$ -DG (AP83) was used to assess loading. **C:** These photomicrographs illustrate the muscle biopsy histopathology and immunostaining abnormalities of representative individuals with *GMPPB* variants. The hematoxylin and eosin images show dystrophic pathology in LGMD case P3 (C1) and CMD-CRB case P9 (C2). Muscle biopsies were taken at 15 and 2 years of age, respectively. Immunofluorescence images from the same two muscle biopsies show reduced staining for  $\alpha$ -dystroglycan with two different glycoepitope-dependent antibodies, IIH6 and VIA4-1. A control muscle biopsy is shown in panels C3, 6, 9, and 12. P3 muscle is shown in panels C4, 7, 10, and 13. P9 muscle is shown in panels C5, 8, 11, and 14. Dystrophin, C3-5;  $\alpha$ -dystroglycan (IIH6), C6-8;  $\alpha$ -dystroglycan (VIA4-1), C9-11;  $\beta$ -dystroglycan, C12-14. The scale bar in panel C2 equals 100  $\mu$ m in panels C1 and C2; the scale bar in panel C14 equals 100  $\mu$ m in panels C3-14.

Cabrera-Serrano et al., 2015]. These individuals present with hyperCKemia, limb-girdle pattern weakness or muscle pain sometime after the age of 10 years (16 of 17), are able to walk or run independently (17 of 17), and most have normal intelligence (12 of 17, the remaining five have borderline intelligence [two of five] or intellectual disability [three of five]). Cataracts (three of 14), abnormal electrocardiogram (three of 14), and epilepsy (one of 14), are uncommon in reported individuals with this variant. Thus, the *c.79G>C* (p.D27H) variant is associated with a relatively mild phenotype among individuals with *GMPPB*-associated dystroglycanopathy. In contrast, the

*c.860G>A* (p.R287Q) variant, which has been seen in 11 individuals from nine unrelated families [Carss et al., 2013; Raphael et al., 2014; Belaya et al., 2015; Cabrera-Serrano et al., 2015], is associated with a congenital muscular dystrophy phenotype. These individuals have delayed motor developmental (10 of 11) and intellectual disability (10 of 11). Most achieve independent ambulation (eight of 11). Results of brain MRI are reported for eight individuals and five are abnormal with cerebellar hypoplasia. Other variable clinical features in the *c.860G>A* cases include epilepsy (six of nine) and strabismus (five of nine). Compound heterozygous individuals with both the

c.79G>C (p.D27H) and c.860G>A (p.R287Q) variants have yet to be reported.

Previous studies have examined the subcellular localization of selected *GMPPB* variants in C2C12 myoblasts [Carss et al., 2013; Belaya et al., 2015]. Normal cytoplasmic localization of *GMPPB* was seen in the c.79G>C (p.D27H) variant cells, whereas cytoplasmic aggregation of *GMPPB* was seen in cells with the c.860G>A (p.R287Q) variant. The c.79G>C (p.D27H) variant is located within the nucleotidyl transferase domain of *GMPPB*, suggesting that it may reduce the efficacy of the enzyme's catalytic function to a milder degree respective to other pathogenic variants. The cytoplasmic aggregation of *GMPPB* in c.860G>A (p.R287Q) variant cells suggests that protein misfolding and subsequent reduction in cellular *GMPPB* activity may be responsible for the relatively severe phenotype seen in individuals with this variant. Like the c.860G>A (p.R287Q) variant, *GMPPB* aggregation was also seen in c.95C>T (p.P32L) variant cells, a variant that has been seen in a total of five cases in literature [P5 and P6 in Carss et al., 2013; P1, P2, and p8 in Cabrera-Serrano et al., 2015]. The single novel variant identified in our P9 (c.94C>T, p.P32S) makes a predicted serine substitution in the same codon altered by the pathogenic c.95C>T (p.P32L) variant, further supporting the predicted pathogenicity of the c.94C>T (p.P32S) variant in our P9. Interestingly, four of the six individuals with cerebellar hypoplasia have *GMPPB* variants leading to amino acid substitutions in this highly conserved proline at codon 32 [P9 reported here, P5 and P6 in Carss et al., 2013; P8 in Cabrera-Serrano et al., 2015].

*GMPPB*-associated dystroglycanopathies present with a wide phenotypic spectrum and the current cases, together with those previously published, allow preliminary genotype–phenotype observations for the emerging common pathogenic variants, c.79G>C (p.D27H) and c.860G>A (p.R287Q). Muscle biopsy with immunostaining for glycosylated  $\alpha$ -dystroglycan can suggest a dystroglycanopathy, or support the diagnosis when novel variants are identified. Unlike several other dystroglycanopathy genotypes [Willer et al., 2012], fibroblast cultures show only subtle, if any, defects in  $\alpha$ -glycosylation status [Carss et al., 2013]. Additional experience with the current cohort of cases and the identification of additional cases will be required to more completely understand genotype–phenotype relationships and the natural history of *GMPPB*-associated dystroglycanopathy. Management remains symptomatic; however, a subset of individuals with *GMPPB* variants may respond to medications used to treat congenital myasthenic syndromes [Belaya et al., 2015].

## Acknowledgments

K.P.C. is an investigator of the Howard Hughes Medical Institute. Muscle biopsy immunostaining was performed by Terese Nelson. Carrie Stephan coordinated research subject visits. Figures were assembled with the assistance of Joel Carl. B.S.J. and K.D.M. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies that produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926), and the Heart GO Sequencing Project (HL-103010).

B.S.J., first author, was primarily responsible for compiling data and writing the manuscript. K.D.M., corresponding author, and S.A.M. are joint last authors and were responsi-

ble for project conception and data collection. D.S., T.M., M.S., and V.A.S. collected clinical information. T.W., M.O.C., T.L.W., and K.P.C. contributed data, technical, and scientific expertise. All authors contributed to critical review and revision of the manuscript.

B.S.J., T.W., D.S., M.O.C., T.M., M.S., and V.A.S. report no disclosures relevant to this manuscript. T.L.W. was employed by Prevention Genetics, LLC. K.P.C. received speaker fees from Pfizer and Alexion pharmaceuticals. S.A.M. performs fee for service muscle biopsy assays for Sarepta Therapeutics. K.D.M. is a consultant for aTyr pharma and is a site principal investigator for industry sponsored trials for Sarepta Therapeutics, Horizon pharma, Shire ViroPharma, Eli Lilly, Pfizer, and Biomarin. There are no direct conflicts with the work reported here.

## References

- Barresi R, Campbell KP. 2006. Dystroglycan: from biosynthesis to pathogenesis of human disease. *J Cell Sci* 119:199–207.
- Belaya K, Rodriguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME, Petty R, Walls TJ, Sedghi M, Basiri K, Yue WW, Sarkozy A, et al. 2015. Mutations in *GMPPB* cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. *Brain* 138(Pt 9):2493–2504.
- Bharucha-Goebel DX, Neil E, Donkervoort S, Dastgir J, Wiggs E, Winder TL, Moore SA, Iannaccone ST, Bonnemann CG. 2015. Intrafamilial variability in *GMPPB*-associated dystroglycanopathy: broadening of the phenotype. *Neurology* 84:1495–1497.
- Bonnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreira A, Muntoni F, Sewry C, Beroud C, Mathews KD, Moore SA, Bellini J, et al. 2014. Diagnostic approach to the congenital muscular dystrophies. *Neuromuscul Disord* 24:289–311.
- Cabrera-Serrano M, Ghaoui R, Ravenscroft G, Johnsen RD, Davis MR, Corbett A, Reddel S, Sue CM, Liang C, Waddell LB, Kaur S, Lek M, et al. 2015. Expanding the phenotype of *GMPPB* mutations. *Brain* 138:836–844.
- Carss KJ, Stevens E, Foley AR, Cirak S, Riemersma M, Torelli S, Hoischen A, Willer T, van Scherpenzeel M, Moore SA, Messina S, Bertini E, et al. 2013. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan. *Am J Hum Genet* 93:29–41.
- Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: <http://evs.gs.washington.edu/EVS/>) [May, 2015].
- Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, Jimenez-Mallebrera C, Mercuri E, et al. 2007. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. *Brain* 130:2725–2735.
- Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, et al. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. *Nature* 418:417–422.
- Moore SA, Saito F, Chen J, Michele DE, Henry MD, Messing A, Cohn RD, Ross-Barta SE, Westra S, Williamson RA, Hoshi T, Campbell KP. 2002. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. *Nature* 418:422–425.
- Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, et al. 2006. Limb-girdle muscular dystrophy in the United States. *J Neuropathol Exp Neurol* 65:995–1003.
- Raphael AR, Couthouis J, Sakamuri S, Siskind C, Vogel H, Day JW, Gitler AD. 2014. Congenital muscular dystrophy and generalized epilepsy caused by *GMPPB* mutations. *Brain Res* 1575:66–71.
- Saito F, Moore SA, Barresi R, Henry MD, Messing A, Ross-Barta SE, Cohn RD, Williamson RA, Sluka KA, Sherman DL, Brophy PJ, Schmelzer JD, et al. 2003. Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. *Neuron* 38:747–758.
- Willer T, Lee H, Lommel M, Yoshida-Moriguchi T, de Bernabe DB, Venzke D, Cirak S, Schachter H, Vajsar J, Voit T, Muntoni F, Loder AS, et al. 2012. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. *Nat Genet* 44:575–580.